close
close
  • February 18, 2025
Genmab Holds R&D Update and ASH Data Review Meeting for 2024 | 11.12.24

Genmab Holds R&D Update and ASH Data Review Meeting for 2024 | 11.12.24

Press release

  • Event will be held virtually via live webcast and archived at www.genmab.com

Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024, at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast. To register for the webcast, click https://genmab-post-ash-2024.open-exchange.net/. An archive of the webcast will be available on Genmab’s website.

This meeting is not an official program of the ASH Annual Meeting.

About Genmab
Genmab is a global biotechnology company whose core purpose is to guide its unstoppable team in the pursuit of improving the lives of patients with innovative and differentiated antibody therapies. For 25 years, the passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates and an immune checkpoint of the next generation modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody drugs.

Founded in 1999, Genmab is headquartered in Copenhagen, Denmark, with an international presence in North America, Europe and Asia Pacific. For more information please visit Genmab.com‘And follow us LinkedIn And X.

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: [email protected]

Andrew Carlsen, Vice President and Head of Investor Relations
T: +45 3377 9558; E: [email protected]

This press release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. Important factors that could cause our actual results or performance to differ materially include risks associated with the preclinical and clinical development of products, uncertainties regarding the outcome and conduct of clinical trials, including unforeseen safety issues, uncertainties regarding to the production of products, the lack of market acceptance of our products, our inability to manage growth, the competitive environment relating to our operations and markets, our inability to attract and retain sufficient qualified personnel, the non- enforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology that could make our products or technologies obsolete, and other factors. For further discussion of these risks, please refer to the risk management sections of Genmab’s most recent financial reports, available at www.genmab.com
and the risk factors included in Genmab’s most recent annual report on Form 20-F and other documents with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab undertakes no obligation to update or revise any forward-looking statements contained in this press release, nor to update any such statements to reflect subsequent events or circumstances after the date made or in connection with actual results, unless required by law .

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®HexElect®
and KYSO®.

Media release no. ik21
CVR no. 2102 3884
LEI code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark